JP2016522830A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016522830A5 JP2016522830A5 JP2016514532A JP2016514532A JP2016522830A5 JP 2016522830 A5 JP2016522830 A5 JP 2016522830A5 JP 2016514532 A JP2016514532 A JP 2016514532A JP 2016514532 A JP2016514532 A JP 2016514532A JP 2016522830 A5 JP2016522830 A5 JP 2016522830A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- pbmc
- use according
- derived
- degeneration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 11
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 230000002757 inflammatory effect Effects 0.000 claims 7
- 210000001616 monocyte Anatomy 0.000 claims 6
- 208000030533 eye disease Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 4
- 201000007737 Retinal degeneration Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000002780 macular degeneration Diseases 0.000 claims 3
- 210000001328 optic nerve Anatomy 0.000 claims 3
- 230000002207 retinal effect Effects 0.000 claims 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 2
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 claims 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 2
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 claims 2
- 230000003412 degenerative effect Effects 0.000 claims 2
- 229930195712 glutamate Natural products 0.000 claims 2
- 206010023332 keratitis Diseases 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 210000002569 neuron Anatomy 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000008929 regeneration Effects 0.000 claims 2
- 238000011069 regeneration method Methods 0.000 claims 2
- 210000001525 retina Anatomy 0.000 claims 2
- 230000001988 toxicity Effects 0.000 claims 2
- 231100000419 toxicity Toxicity 0.000 claims 2
- 206010055665 Corneal neovascularisation Diseases 0.000 claims 1
- 201000001925 Fuchs' endothelial dystrophy Diseases 0.000 claims 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 1
- 201000002287 Keratoconus Diseases 0.000 claims 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 1
- 208000022873 Ocular disease Diseases 0.000 claims 1
- 241001420836 Ophthalmitis Species 0.000 claims 1
- 206010039705 Scleritis Diseases 0.000 claims 1
- 206010064996 Ulcerative keratitis Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 201000000159 corneal neovascularization Diseases 0.000 claims 1
- 201000007717 corneal ulcer Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000007972 injectable composition Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 201000004614 iritis Diseases 0.000 claims 1
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 1
- 206010023365 keratopathy Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000010403 panophthalmitis Diseases 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361826159P | 2013-05-22 | 2013-05-22 | |
| US61/826,159 | 2013-05-22 | ||
| US201361915069P | 2013-12-12 | 2013-12-12 | |
| US61/915,069 | 2013-12-12 | ||
| PCT/IL2014/050463 WO2014188436A1 (en) | 2013-05-22 | 2014-05-22 | Human monocyte sub-population for treatment of eye diseases and disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016522830A JP2016522830A (ja) | 2016-08-04 |
| JP2016522830A5 true JP2016522830A5 (cg-RX-API-DMAC7.html) | 2017-06-29 |
| JP6474082B2 JP6474082B2 (ja) | 2019-02-27 |
Family
ID=51933057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016514532A Expired - Fee Related JP6474082B2 (ja) | 2013-05-22 | 2014-05-22 | 眼疾患および眼障害の治療のためのヒト単球亜集団 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10188679B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2999479B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6474082B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102257163B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN105377273A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014269935B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112015029299A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2913274C (cg-RX-API-DMAC7.html) |
| IL (1) | IL242694B (cg-RX-API-DMAC7.html) |
| MX (1) | MX2015016062A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014188436A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013088441A1 (en) * | 2011-12-14 | 2013-06-20 | Yeda Research And Development Co. Ltd | Human monocyte sub-population for treatment of central nervous system injury |
| US11162070B2 (en) | 2015-09-08 | 2021-11-02 | FUJIFILM Cellular Dynamics, Inc. | MACS-based purification of stem cell-derived retinal pigment epithelium |
| DE102017125335B4 (de) * | 2017-10-27 | 2019-10-17 | Epiontis Gmbh | Amplikon-Region als epigenetischer Marker zur Identifizierung von Immunzellen, insbesondere nicht-klassischer Monozyten |
| KR102228401B1 (ko) * | 2018-07-05 | 2021-03-16 | 고려대학교 산학협력단 | 유리체 절제술 및 안구 내 mnu 주입과 제거를 이용한 망막 변성 동물 모델의 제조방법 및 이를 이용한 망막 변성 동물 모델 |
| MX2022007107A (es) * | 2019-12-11 | 2022-11-14 | Myeloid Therapeutics Inc | Composiciones celulares terapeuticas y metodos de preparacion y usos de las mismas. |
| CN116440253A (zh) * | 2023-02-27 | 2023-07-18 | 中山大学中山眼科中心 | 修复型免疫细胞亚群的诱导方法及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6267955B1 (en) | 1995-09-15 | 2001-07-31 | Yeda Research And Development Co. Ltd. | Mononuclear phagocytes and their use to promote axonal regeneration |
| US5800812A (en) | 1995-09-15 | 1998-09-01 | Yeda Research And Development Co. Ltd. | Methods of use of mononuclear phagocytes to promote axonal regeneration |
| AU2002353465B2 (en) | 2001-11-21 | 2008-10-16 | Yeda Research And Development Co. Ltd. | Process for the manufacture of human mononuclear phagocytic leukocytes |
| RU2418856C2 (ru) * | 2005-02-24 | 2011-05-20 | Дзе Скриппс Рисерч Инститьют | Изолированные популяции миелоидоподобных клеток костного мозга и способы лечения с ними |
| AU2010216374A1 (en) * | 2009-02-20 | 2011-08-18 | The Scripps Research Institute | Isolated monocyte populations and related therapeutic applications |
| WO2013088441A1 (en) * | 2011-12-14 | 2013-06-20 | Yeda Research And Development Co. Ltd | Human monocyte sub-population for treatment of central nervous system injury |
-
2014
- 2014-05-22 BR BR112015029299A patent/BR112015029299A2/pt not_active Application Discontinuation
- 2014-05-22 US US14/898,732 patent/US10188679B2/en active Active
- 2014-05-22 JP JP2016514532A patent/JP6474082B2/ja not_active Expired - Fee Related
- 2014-05-22 WO PCT/IL2014/050463 patent/WO2014188436A1/en not_active Ceased
- 2014-05-22 AU AU2014269935A patent/AU2014269935B2/en not_active Ceased
- 2014-05-22 CN CN201480039692.9A patent/CN105377273A/zh active Pending
- 2014-05-22 CA CA2913274A patent/CA2913274C/en active Active
- 2014-05-22 KR KR1020157036168A patent/KR102257163B1/ko not_active Expired - Fee Related
- 2014-05-22 MX MX2015016062A patent/MX2015016062A/es unknown
- 2014-05-22 EP EP14801769.2A patent/EP2999479B1/en active Active
-
2015
- 2015-11-19 IL IL242694A patent/IL242694B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3045733C (en) | Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases | |
| JP2012505162A5 (cg-RX-API-DMAC7.html) | ||
| Semba et al. | Brimonidine prevents neurodegeneration in a mouse model of normal tension glaucoma | |
| JOP20170147B1 (ar) | تركيبة عينية تشتمل على زيت الخروع ودهون ثلاثية متوسطة السلسلة | |
| MX2010003774A (es) | Formulaciones oftalmicas acuosas. | |
| WO2015138628A8 (en) | Use of aav-expressed m013 protein as an anti-inflammatory therapeutic | |
| EA201170551A1 (ru) | Способы лечения заболеваний глаз | |
| Grieb et al. | Citicoline: a food beneficial for patients suffering from or threated with glaucoma | |
| RU2014123472A (ru) | Производные 4-прегенен-11ss-17-21-триол-3,20-диона для лечения глазных болезней | |
| JP2013528563A5 (cg-RX-API-DMAC7.html) | ||
| RU2017116974A (ru) | Офтальмологическая композиция, содержащая циклоспорин и трегалозу | |
| MY203247A (en) | Anti-trkb monoclonal antibodies and methods of use | |
| RU2014125426A (ru) | Защитное средство для роговицы и конъюнктивы или супрессивное средство при кератоконъюнктивальном нарушении | |
| JP2017525758A5 (cg-RX-API-DMAC7.html) | ||
| WO2013184650A3 (en) | Treatment of ocular inflammatory diseases using laquinimod | |
| Scholl et al. | The use of neuroprotective agents in treating geographic atrophy | |
| AR079683A1 (es) | Formulacion topica oftalmica de peptidos | |
| EA202192183A1 (ru) | Композиции, обладающие активностью удаления липофусцина из клеток сетчатки | |
| BR112015029299A2 (pt) | subpopulação de monócitos humanos para tratamento de doenças e distúrbios oculares | |
| JP2015514760A5 (cg-RX-API-DMAC7.html) | ||
| CL2020001426A1 (es) | Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo. | |
| NZ622403A (en) | Method for screening an agent being useful for the treatment of dry eye and/or corneal and conjunctival lesion and a pharmaceutical composition obtained by the method | |
| Amalnath et al. | Ocular signs in Wilson disease | |
| Park et al. | The analysis of peripapillary RNFL, macula and macular ganglion cell layer thickness in patients with monocular amblyopia using SD-OCT | |
| Li et al. | Analysis of the correlation between tear film changes of allergic conjunctivitis and dry eye |